Clinical & Experimental Metastasis

, Volume 35, Issue 8, pp 753–761 | Cite as

Lung cancer with bone metastases in the United States: an analysis from the Surveillance, Epidemiologic, and End Results database

  • Wangmi Liu
  • Jiayan WuEmail author
Research Paper


The present study used the Surveillance, Epidemiology and End Results (SEER) database to identify demographic and prognostic characteristics of lung cancer with bone metastases in the United States from 2010 to 2014. 30,364 patients with metastatic lung cancer to bones were identified in the SEER database. Their information on the basic characteristics and the histological signatures of the cancer was extracted and analyzed. Joinpoint analysis was used to test the trends in annual percentage change (APC) of the incidence. 1-year survival rate among patients with metastatic lung cancer to bones was only 20.2%, and median survival time was about 3.0 months for those patients. Young age, female sex, race other than white and black, tumor in lobes, smaller tumor, adenocarcinoma, and surgery for primary site were associated with a significant survival benefit. APC of the incidence almost increased steadily on the whole and reached the level of statistical significance among the patients older than age 60. Although there are some signatures associated with better prognosis, the overall outcome remains very poor in patients with metastatic lung cancer to bones. In addition, the incidence of lung cancer with bone metastases is increasing in certain subgroups in the United States.


Lung cancer Bone metastases SEER database Epidemiologic study Survival analysis 



Surveillance, Epidemiology and End Results


Annual percentage change


Non-small-cell lung cancer


Small-cell lung cancer


Skeletal related events


Hazard ratios


Overall survival


Compliance with ethical standards

Conflict of interest

The author reports no conflict of interest in this work.

Supplementary material

10585_2018_9943_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 KB)


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  2. 2.
    Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544CrossRefGoogle Scholar
  3. 3.
    Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594CrossRefGoogle Scholar
  4. 4.
    Groot MT, Boeken Kruger CG, Pelger RC et al (2003) Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 43:226–232CrossRefGoogle Scholar
  5. 5.
    Hillner BE, Weeks JC, Desch CE et al (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79CrossRefGoogle Scholar
  6. 6.
    Delea T, Langer C, McKiernan J et al (2004) The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67:390–396CrossRefGoogle Scholar
  7. 7.
    Sathiakumar N, Delzell E, Morrisey MA et al (2013) Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006. Lung India 30:20–26CrossRefGoogle Scholar
  8. 8.
    Sun JM, Ahn JS, Lee S et al (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71:89–93CrossRefGoogle Scholar
  9. 9.
    National Cancer Institute (2005) Surveillance, Epidemiology and End Results (SEER) program. National Cancer Institute, RockvilleGoogle Scholar
  10. 10.
    Program JR (2016) Version Statistical Research and Applications Branch, National Cancer Institute, BethesdaGoogle Scholar
  11. 11.
    Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157CrossRefGoogle Scholar
  12. 12.
    Sekine I, Nokihara H, Yamamoto N et al (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65:219–222CrossRefGoogle Scholar
  13. 13.
    Tsuya A, Kurata T, Tamura K et al (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57:229–232CrossRefGoogle Scholar
  14. 14.
    Su S, Hu Y, Ouyang W et al (2014) The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy. Radiat Oncol 9:290CrossRefGoogle Scholar
  15. 15.
    Fan H, Shao ZY, Xiao YY et al (2015) Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open 5:e009419CrossRefGoogle Scholar
  16. 16.
    Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736CrossRefGoogle Scholar
  17. 17.
    Owonikoko TK, Ragin CC, Belani CP et al (2007) Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25:5570–5577CrossRefGoogle Scholar
  18. 18.
    Ramalingam S, Pawlish K, Gadgeel S et al (1998) Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 16:651–657CrossRefGoogle Scholar
  19. 19.
    Santini D, Barni S, Intagliata S et al (2015) Natural history of non-small-cell lung cancer with bone metastases. Sci Rep 5:18670CrossRefGoogle Scholar
  20. 20.
    Veluswamy RR, Ezer N, Mhango G et al (2015) Limited resection versus lobectomy for older patients with early-stage lung cancer: impact of histology. J Clin Oncol 33:3447–3453CrossRefGoogle Scholar
  21. 21.
    Lally BE, Zelterman D, Colasanto JM et al (2006) Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24:2998–3006CrossRefGoogle Scholar
  22. 22.
    Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6243s9sCrossRefGoogle Scholar
  23. 23.
    Jemal A, Ma J, Rosenberg PS et al (2012) Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol 30:2739–2744CrossRefGoogle Scholar
  24. 24.
    Jemal A, Thun MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694CrossRefGoogle Scholar
  25. 25.
    Kuchuk M, Addison CL, Clemons M et al (2013) Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2:22–29CrossRefGoogle Scholar
  26. 26.
    Gomez DR, Blumenschein GR Jr, Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682CrossRefGoogle Scholar
  27. 27.
    Parikh RB, Cronin AM, Kozono DE et al (2014) Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89:880–887CrossRefGoogle Scholar
  28. 28.
    Ramsey SD, Howlader N, Etzioni RD et al (2004) Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 22:4971–4978CrossRefGoogle Scholar
  29. 29.
    Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939–945CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.The Second Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina
  2. 2.Shanghai Tenth People’s HospitalTongji University School of MedicineShanghaiChina

Personalised recommendations